BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Karus Therapeutics Commences Preclinical Development of Novel Immune and Inflammation Programmes


11/2/2010 11:37:04 AM

Chilworth, UK - 2 November 2010 - Karus Therapeutics Ltd, a company engaged in the discovery and development of de novo designed molecular-targeted small molecule drugs to treat inflammation and cancer, has commenced preclinical development of its HDAC6 and PI3-Kinase inhibitor programmes for the treatment of immune and inflammatory diseases such as rheumatoid arthritis (RA). Karus aims to initiate clinical trials for both programmes in 2011.

Karus’s highly potent and selective small molecule inhibitors of HDAC6 and PI3-Kinase p110-delta regulate T-helper 17 (Th17) cell function and inhibit the production of interleukins 17, 21 and 23 (IL-17, IL-21, IL-23). Th17 cells play a key role in the pathogenesis of immune and inflammatory diseases such as RA, multiple sclerosis, psoriasis, systemic lupus erythematosus and organ transplant rejection. Karus’s compounds have been shown to inhibit the production of Th17 cell pro-inflammatory cytokines and, in preclinical models of RA, display efficacy comparable to the anti-TNF biologics.

Simon Kerry, CEO of Karus Therapeutics said: “There is a significant opportunity for the development of an important new class of anti-inflammatory drugs which selectively target Th17 cells via a novel mechanism of action. We are very excited by the potential of our development candidates as oral treatments for RA and other inflammatory diseases.” Karus’s CSO, Dr Stephen Shuttleworth, will be presenting preclinical data from Karus’s PI3K p110-delta and dual p110-delta/beta inhibitor programmes, at the inaugural Targeting the PI3K Pathway conference held as part of Cambridge Healthtech Institute’s 8th International Discovery on Target conference in Boston between 2-3 November 2010. Dr Shuttleworth’s presentation, entitled, “Design and Development of Novel, Isoform-Selective PI3K Inhibitors for the Treatment of Immune-Inflammatory Diseases and Cancer”, will discuss inhibitors of PI3K p110-delta, already acknowledged as an important target in the treatment of immune and inflammatory conditions, and inhibitors of PI3K p110-beta, which is emerging as an important target in these disease areas.

About Karus Therapeutics

Karus Therapeutics commenced operations in 2006 and is focused on the discovery, development and partnering of innovative, molecular-targeted, small-molecule drugs to treat cancer and inflammation. The Company's primary focus is the development of proprietary drugs that have best-in-class potential to treat inflammatory disease and cancer by targeting epigenetic mechanisms and lipid kinase signalling. Karus’s development programs include gold-standard potent and selective HDAC inhibitors and innovative, isoform-selective PI3-Kinase inhibitors. Karus is a private company located on the Southampton Science Park, UK.

Further information: http://www.karustherapeutics.com

For more information contact: At the company: Simon Kerry, CEO +44 (0)2380 111360 s.kerry@karustherapeutics.com

Media: College Hill Life Sciences Nicole Yost, Jayne Crook +44 (0)20 7457 2020 karus@collegehill.com



Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES